The Role of PI3K Isoforms in Autoimmune Disease

Research output: Chapter or section in a book/report/conference proceedingChapter or section

1 Citation (SciVal)

Abstract

Aberrant overactivation of the immune system can give rise to chronic and persistent self-attack, culminating in autoimmune disease. This is currently managed therapeutically using potent immunosuppressive and anti-inflammatory drugs. Class I phosphoinositide-3-kinases (PI3Ks) have been identified as ideal therapeutic targets for autoimmune diseases given their wide-ranging roles in immunological processes. Although progress has been hampered by issues such as poor drug tolerance and drug resistance, several PI3K inhibitors have now received regulatory approval with many others in development, including several intended to suppress the immune response in autoimmune and inflammatory diseases. This chapter reviews the evidence for contribution of aberrant PI3K activity to a range of autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and type I diabetes) and possible therapeutic application of isoform-specific PI3K inhibitors as immunosuppressive drugs.

Original languageEnglish
Title of host publicationCurrent Topics in Microbiology and Immunology
EditorsM. Dominguez-Villar
Place of PublicationCham, Switzerland
PublisherSpringer Science and Business Media Deutschland GmbH
Pages337-347
Number of pages11
ISBN (Electronic)9783031065668
ISBN (Print)9783031065651
DOIs
Publication statusPublished - 16 Oct 2022

Publication series

NameCurrent Topics in Microbiology and Immunology
Volume436
ISSN (Print)0070-217X
ISSN (Electronic)2196-9965

Keywords

  • Arthritis
  • Autoimmune
  • Diabetes
  • Inhibitors
  • Leukocytes
  • Lupus
  • Multiple Sclerosis
  • PI3K

ASJC Scopus subject areas

  • Immunology and Allergy
  • Microbiology
  • Immunology
  • Microbiology (medical)

Fingerprint

Dive into the research topics of 'The Role of PI3K Isoforms in Autoimmune Disease'. Together they form a unique fingerprint.

Cite this